Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy

• Published in: Journal of Immunotherapy and Precision Oncology Vol. 4; no. 3; pp. 117 - 128
• Main Authors: Lee, Sophia S, Verstovsek, Srdan, Pemmaraju, Naveen
• Format: Journal Article
• Language: English
• Published: United States Innovative Healthcare Institute 01.08.2021
• Subjects: jak inhibitor; mpn; myelofibrosis; myeloproliferative neoplasms; novel therapy; Review; ruxolitinib; myeloproliferative neoplasms; JAK inhibitor; myelofibrosis; MPN; ruxolitinib; novel therapy
• ISSN: 2666-2345; 2590-017X
• DOI: 10.36401/JIPO-20-35

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders that consist classically of polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). Janus kinase (JAK) inhibitors have become the standard of therapy in treating patients with intermediate- to higher-risk MF. However, JAK inhibitor (JAKi) treatment can be associated with development of resistance, suboptimal response, relapse, or treatment-related adverse effects. With no approved therapies beyond the JAKi class, the estimated median survival, post JAKi failure, is approximately two years or less; therefore, novel therapies are urgently needed in the MF field. In this review, we discuss ruxolitinib use in MPNs as well as causes of ruxolitinib failure or discontinuation. In addition, we review novel therapies being investigated alone or in combination with JAKi administration. We summarize concepts and mechanisms behind emerging novel therapies being studied for MPNs. This review of emerging novel therapies outlines several novel mechanisms of agents, including via promotion of apoptosis, alteration of the microenvironment, activation or inactivation of various pathways, targeting fibrosis, and telomerase inhibition.